Yahoo! FinanceHome - Yahoo! - Help

Market Guide

[ Stock Screener | Company & Fund Index | Financial Glossary ]

Profile - Novavax, Inc. (NasdaqNM:NVAX)
As of 31-Aug-2001
Enter symbol:
symbol lookup

 
More Info: Quote | Chart | News | Profile | Research | Msgs | Insider
Recent Events
Aug 23Price hit new 52-week high ($14.01)
Location
8320 Guilford Road
Columbia, MD 21046
Phone: (301) 854-3900
Fax: (301) 854-3901
Email: nox@novavax.com
Employees (last reported count): 127
Financial Links
 ·Historical Quote Data
 ·Raw SEC Filings at sec.gov
Competitors:
 ·Sector: Healthcare
 ·Industry: Biotechnology & Drugs
Company Websites
 ·Home Page
 ·Investor Relations
 ·Yahoo! Category

 ·Search Yahoo! for related links...

Ownership
·Insider and 5%+ Owners: 67%
·Over the last 6 months:
 · 4 insider buys; 8,000  shares
 · 11 insider sells; 592.0K shares
  (3.7% of insider shares)
·Institutional: 15% (45% of float)
(48 institutions)
·Net Inst. Selling: 657.0K shares (+24.13%)
(prior quarter to latest quarter)
More From Market Guide
 ·Highlights
 ·Performance
 ·Ratio Comparisons
Business Summary
Novavax, Inc. is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. The Company's product development efforts are focused on the research and development of proprietary drug delivery and vaccine technologies and the applications of those technologies. Its technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. In addition, the Company is engaged in contract research and development and Phase I and Phase II vaccine-manufacturing of human vaccines for its own use, for government laboratories and for other vaccine companies.
More from Market Guide: Expanded Business Description

Financial Summary
Novavax, Inc. is a biopharmaceutical company that researches and develops drug products for women's health, infectious diseases and cancer. For the six months ended 6/30/01, revenues totaled $12.9 million up from $1.3 million. Net loss increased 1% to $4 million. Revenues benefitted from the 12/00 acquisition of Fielding Pharmaceutical Company. Higher losses reflect increased acquisition related sales and market expenses and higher debt levels.
More from Market Guide: Significant Developments

Officers[Insider Trade Data]
FY2000 Pay

Denis O'Donnell, M.D., 47
Chairman
$125K
John Spears, 51
Pres, CEO, Director
453K
Dennis Genge, 48
CFO, VP, Treasurer
--  
James Mirto, 58
Sr. VP, COO
131K
D.Craig Wright, M.D., 50
CSO
229K
Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc..
More from Market Guide on Officers & Directors:
Expanded List, Bios, Compensation, Options
Statistics at a Glance -- NasdaqNM:NVAXAs of 31-Aug-2001
Price and Volume
52-Week Low
on 5-Apr-2001
$6.35 
Recent Price$13.25 
52-Week High
on 23-Aug-2001
$14.01 
Beta1.35 
Daily Volume (3-month avg)148.3K
Daily Volume (10-day avg)183.0K
Stock Performance
[one-year price graph]
big chart [1d | 5d | 3m | 6m | 1y | 2y | 5y | max]
52-Week Change+45.2%
52-Week Change
relative to S&P500
+94.8%
Share-Related Items
Market Capitalization$302.8M
Shares Outstanding22.9M
Float7.50M
Dividends & Splits
Annual Dividendnone 
Last Splitnone 
Per-Share Data
Book Value (mrq)$1.30 
Earnings (ttm)-$0.60 
Earnings (mrq)-$0.08 
Sales (ttm)$0.67 
Cash (mrq)$0.51 
Valuation Ratios
Price/Book (mrq)10.16 
Price/EarningsN/A 
Price/Sales (ttm)19.72 
Income Statements
Sales (ttm)$14.1M
EBITDA (ttm)-$10.2M
Income available to common (ttm)-$12.2M
Profitability
Profit Margin (ttm)-86.9%
Operating Margin (ttm)-87.3%
Fiscal Year
Fiscal Year EndsDec 31
Most recent quarter30-June-2001
Management Effectiveness
Return on Assets (ttm)-30.70%
Return on Equity (ttm)-51.53%
Financial Strength
Current Ratio (mrq)2.91 
Debt/Equity (mrq)0.68 
Total Cash (mrq)$11.4M
Short Interest
As of 8-Aug-2001
Shares Short241.0K
Percent of Float3.2%
Shares Short
(Prior Month)
0 
Short Ratio0.98 
Daily Volume246.0K
See Profile Help for a description of each item above;   K = thousands;   M = millions;   mrq = most-recent quarter;   ttm = trailing twelve months;   (as of 30-June-2001)

Market Guide offers more in-depth Company Research, Stock Screening, and Hottest Stocks and Industries on over 10,000 U.S. Equities.


Copyright © 2001 Yahoo! Inc. All Rights Reserved. Privacy Policy - Terms of Service
Company information Copyright Market Guide. Historical chart data and daily updates provided by Commodity Systems, Inc. (CSI). Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Yahoo nor any of its data or content providers (such as Market Guide, CSI, etc.) shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon.